

REPORT ID AF-2026-663577	VERIFICATION CODE MUZU-TP2C	CLIENT China Peptide Source	STATUS ACTIVE
PRODUCT HGH 191aa Somatropin 10 IU Vial	BATCH / LOT HGHS-14E8	SAMPLE RECEIVED Jul 28, 2026	ANALYSIS DATE Jul 30, 2026

CORE ANALYTICAL PANEL

TEST PARAMETER	METHOD	RESULT	SPECIFICATION	STATUS
Purity	SEC-HPLC (Purity / Area %)	99.47%	≥99.00%	Conforms
Identity	LC-MS	22124.3 Da	22124.0 ± 2 Da	Conforms
Potency	Validated Bioassay	100.1%	90.0–110.0%	Conforms

BIOSAFETY & SCREENING

SAFETY TEST	METHOD	OBSERVED LEVEL	LIMIT	STATUS
Endotoxin Assay (LAL)	LAL	0.516 EU/mg	≤ 5.0 EU/mg	Pass
Heavy Metal Screen (ICP-MS)	ICP-MS	0.063 ppm	< 0.1 ppm	Pass

ADDITIONAL ANALYTICAL RESULTS

TEST PARAMETER	METHOD	RESULT	SPECIFICATION	STATUS
Net Content / Potency	Gravimetric	10.03 IU	10 IU Target	Conforms
Appearance	Visual Inspection	Conforms	Product specification	Conforms
Protein/Peptide Integrity	SEC-HPLC (Monomer / Integrity)	99.0%	≥ 95.0%	Conforms
Water Content	Karl Fischer	0.45%	≤ 1.0%	Pass
Aggregates	SEC-HPLC (Aggregates)	< 0.5%	≤ 2.0%	Pass

METHOD & SAMPLE SUMMARY

PRIMARY METHOD SEC-HPLC (Purity / Area %)	MATRIX Lyophilized Powder	SAMPLE SIZE 10 IU
METHOD REFERENCE AF-BIO-QC-01	OVERALL DISPOSITION CONFORMS	

VERIFICATION

MUZU-TP2C

<https://analyticalformulations.com/verify/MUZU-TP2C>

Lab ID: AFL-001 · FormuVerify™



Scan to verify certificate